Valuation : Ocugen, Inc.

Market Cap 361M 311M 293M 267M 499M 34.37B 501M 3.47B 1.34B 17.51B 1.36B 1.33B 55.46B P/E 2026 *
-4.1x
P/E 2027 * -3.8x
Enterprise Value 361M 311M 293M 267M 499M 34.37B 501M 3.47B 1.34B 17.51B 1.36B 1.33B 55.46B EV / Sales 2026 *
75.9x
EV / Sales 2027 * 144x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 week-19.81%
Current month-18.52%
1 month-18.08%
3 months-14.38%
6 months-35.46%
Current year-28.55%
1 week 0.91
Extreme 0.911
1.19
1 month 0.91
Extreme 0.911
1.28
3 years 0.33
Extreme 0.3264
2.35
5 years 0.33
Extreme 0.3264
15.88
Manager TitleAgeSince
Chief Executive Officer 62 26/09/2019
Director of Finance/CFO - 08/02/2026
Chief Operating Officer - 28/02/2026
Director TitleAgeSince
Chairman 62 26/09/2019
Director/Board Member 59 31/08/2013
Director/Board Member 59 31/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-20.23%+0.88%+4.59%+132.16% 451M
-3.24%-7.78%-5.35%+11.20% 48.01B
+0.17%-0.74%+407.28%+546.58% 44.44B
-0.86%-2.60%+35.51%+20.35% 42.67B
-0.14%-2.98%-0.04%+82.21% 39.96B
0.00%-1.72%+13.42%+42.33% 32.75B
-3.44%-2.43% - - 17.74B
-0.78%-1.13%+20.74%+116.26% 16.49B
-0.37%-2.53%+10.91%+30.93% 14.38B
-0.86%-4.60%+76.86%+39.36% 13.4B
Average -1.06%-2.17%+62.66%+113.49% 29.98B
Weighted average by Cap. -1.04%-2.20%+84.44%+131.92%

Financials

2026 *2027 *
Net sales 4.76M 4.09M 3.85M 3.51M 6.57M 453M 6.6M 45.68M 17.66M 231M 17.86M 17.47M 731M 2.5M 2.15M 2.03M 1.85M 3.45M 238M 3.47M 24.01M 9.28M 121M 9.39M 9.18M 384M
Net income -87.21M -75.04M -70.66M -64.38M -120M -8.3B -121M -837M -324M -4.23B -327M -320M -13.39B -97.94M -84.27M -79.35M -72.3M -135M -9.32B -136M -940M -363M -4.75B -368M -360M -15.04B
Net Debt - -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
-
Date Price Change
09/09/26 €0.9110 -20.23%
08/09/26 €1.142 -3.22%
07/09/26 €1.180 -0.34%
04/09/26 €1.184 +3.86%
03/09/26 €1.140 +0.35%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.065USD
Average target price
12.17USD
Spread / Average Target
+1,042.41%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!